Ftse Mib
36.191,17
0,00%
DAX
21.282,18
-0,48%
S&P 500
6.012,28
-1,46%
NASDAQ
19.341,83
-3,07%
Bitcoin
102.676,86
0,60%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CG Oncology Inc (CGON) CG Oncology Inc (CGON) Notizie

CGON

CG Oncology (CGON)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGON
DataOraFonteTitoloSimboloCompagnia
10/01/202522:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CGONCG Oncology Inc
18/12/202400:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CGONCG Oncology Inc
16/12/202422:05GlobeNewswire Inc.CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CGONCG Oncology Inc
13/12/202422:07Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CGONCG Oncology Inc
13/12/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CGONCG Oncology Inc
13/12/202402:19GlobeNewswire Inc.CG Oncology Announces Pricing of Public OfferingNASDAQ:CGONCG Oncology Inc
11/12/202422:09Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:CGONCG Oncology Inc
11/12/202412:17GlobeNewswire Inc.CG Oncology Announces Proposed Public OfferingNASDAQ:CGONCG Oncology Inc
06/12/202414:00GlobeNewswire Inc.SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship AwardNASDAQ:CGONCG Oncology Inc
05/12/202413:00GlobeNewswire Inc.Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
02/12/202414:00GlobeNewswire Inc.CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024NASDAQ:CGONCG Oncology Inc
20/11/202414:00GlobeNewswire Inc.CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual MeetingNASDAQ:CGONCG Oncology Inc
12/11/202414:00GlobeNewswire Inc.CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
11/11/202414:00GlobeNewswire Inc.CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
08/11/202420:17Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CGONCG Oncology Inc
30/08/202414:00GlobeNewswire Inc.CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:CGONCG Oncology Inc
30/08/202402:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CGONCG Oncology Inc
08/08/202414:23GlobeNewswire Inc.CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
08/08/202412:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CGONCG Oncology Inc
18/06/202414:00GlobeNewswire Inc.CG Oncology Initiates Expanded Access Program for Cretostimogene GrenadenorepvecNASDAQ:CGONCG Oncology Inc
06/06/202418:14GlobeNewswire Inc.CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBCNASDAQ:CGONCG Oncology Inc
24/05/202414:00GlobeNewswire Inc.CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
09/05/202414:00GlobeNewswire Inc.CG Oncology Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:CGONCG Oncology Inc
03/05/202417:23GlobeNewswire Inc.Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
26/04/202414:00GlobeNewswire Inc.CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024NASDAQ:CGONCG Oncology Inc
24/04/202416:00GlobeNewswire Inc.CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024NASDAQ:CGONCG Oncology Inc
28/03/202413:00GlobeNewswire Inc.CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual MeetingNASDAQ:CGONCG Oncology Inc
27/02/202414:00GlobeNewswire Inc.CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder CancerNASDAQ:CGONCG Oncology Inc
30/01/202413:00Business WireCG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:CGONCG Oncology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CGON

La tua Cronologia

BIT
11COV
Bearer
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network